PL-1.2 Esketamine: A game changer in depression treatment?
Monday November 30, 2020 from 09:00 to 09:30

Daniel Zigman, Canada

Assistant professor

Department of psychiatry

McGill University


Download the Presentation as a PDF

Esketamine (Spravato) was approved by Health Canada for treatment resistant depression in 2020. It is the first medication in its class available for this indication. This presentation will review the potenital role of esketamine in the treatment of major depressive disorder. 


As a result of attending this session, participants will be able to:

  • Know the definition of treatment resistant depression
  • Know the risks and benefits of esketamine
  • Understand barriers and challenges involved in using esketamine in clincial practice 
Recommended Reading Websites

© 2020 McGill Family Physician Refresher Course